Battlefield-Tested Hemostatic Agents: Their Applications for Hemorrhage Control in Hospital Settings

Battlefield-Tested Hemostatic Agents: Their Applications for Hemorrhage Control in Hospital Settings

by: Herman A. Allison, FNP-C, MSN, RN, CCEMT-Paramedic, PNCCT


Uncontrolled blood loss is a major cause of preventable death worldwide. A severe injury can occur anywhere at any time. Controlling blood loss is an important issue for patient care in the hospital setting. Through the casualties of war, the lifesaving value of quick interventions was developed. Since 2001, new hemostatic agents have advanced the benefits of controlling blood loss. There are unforgettable lessons learned in the preventable deaths of many soldiers and should be passed on to the next generation of health care providers, to include all hospitals up to level I trauma hospitals. This article covers the current hemostatic agents that have been used for more than 17 years on the battlefield and are slowly making their way into the hospital settings. The hemostatic agents covered include QuikClot Combat Gauze, QuikClot Control+, WoundClot Hemostatic Gauze, HemCon Nasal Plug, and RevMedx’s XSTAT hemostatic device. The standard of care should not be affected by the location of a patient, whether that patient is in a remote village overseas, on the battlefield, a rural farm, or at a major metropolitan hospital here in the United States.

There is an old Latin saying Need taught him wit. This became the old English proverb “necessity is the mother of invention.” Across many cultures, throughout history there were setbacks, defeats, and challenges that required a creative solution. These areas include improvements in science, technology, medicine, and the military. We, as humans, learn from our mistakes and setbacks with a mindset of learning and growing to come back and do better.1

The US Military learned from previous wars. Causality survival rates from gunshot wounds and explosive fragments have improved. During World War II the survival rate was 80%, and 84% in the Korean War. Since 2001, the survivability rate is now at 90%.2,3 During the Vietnam War, one Army Medical Corps officer used his experience to improve medical care. Quote from Spurgeon Neel, Colonel, Medical Corps, US Army4: It is appropriate that experience during unavoidable “epidemics of trauma” be exploited in improving our national capability to provide better surgical and medical care for citizens.


As an army soldier in a combat zone, I needed to stop the bleeding of a fellow soldier that was shot by the Russian as- sault weapon—Avtomat Kalashnikova (AK- 47), during an ambush at a remote location. Blood was pumping out with each heartbeat, but all I had was a small gauze dressing in my first-aid pouch. I did all that I could with what I had, but he still bled out and died. Years later, I was again at a remote location, with a wounded casualty bleeding out from the devastating effects of an AK-47 round. This time with the newest hemostatic agent, tourniquets, pre-deployment hands-on training, and the confidence to use these products, I was able to stop the bleeding and save his life.

Lessons learned from the recent war on terror should be passed on to the civilian medical communities and hospital systems. Some areas of military trauma care are years ahead of civilian medicine.5 Seeking out new medical procedures and devices from other sources that could be used to provide the highest quality of care for our patients should be the goal of every medical professional.

Uncontrolled hemorrhage discussion

Uncontrolled hemorrhage is a leading cause of prehospital mortality in military trauma and the second leading cause after civilian trauma.6-10 A severe injury can occur anywhere at any time. Controlling blood loss is an important issue for patient care in both prehospital and in the hospital. We have learned from previous wars the value of quick, easy-to-use interventions that save lives. There are unforgettable lessons learned in the preventable deaths of many soldiers. An example cited by Bellamy6 states that, in Vietnam, 2500 soldiers lost their lives due to lack of hemorrhage control from extremity in- juries. Since 2001, we have learned the ad- vantages of new hemostatic agents and the benefits of controlling blood loss.11-14 These vital discoveries should be passed on to the next generation of health care providers in a hospital setting. This article discusses the cur- rent hemostatic agents that have been used for more than 17 years on the battlefield and are slowly making their way into the civilian sector. Examples will include its uses in the emergency department (ED) trauma room, a cardiac care unit (CCU), the labor and delivery unit, and general surgery. The standard of care should not be affected by the location of a patient, whether that patient is in a remote village overseas, on the battlefield, a rural farm, or a metropolitan hospital in the United States.


QuikClot Combat Gauze Each dressing is a rayon/polyester construction coated with kaolin, aluminum silicate clay, which is a potent coagulation initiator. Dressings come in several forms, which can be tailored for us- age. Since kaolin is an inert mineral that does not contain animal or human proteins, no allergic reaction at the site of application was reported. Contact between kaolin and blood triggers electrostatic rearrangement of factor XII, making factor XII to become activated and initiate intrinsic coagulation pathway. QuikClot Combat Gauze (QCG) accelerates the clotting cascade while creating a stronger and faster clot on a single sheet.11,12 (

QuikClot Control+

This is the first and only hemostatic dressing indicated for temporary control of internal organ space bleeding for patients displaying class III or class IV bleeding, as in damage control surgery a new option that can be delivered quickly, easily, and reliably to of- fer effective, safe, and efficient performance in the worst bleeds. It is available in various sizes, ranging from 5- to 12-inch squares.

WoundClot Hemostatic Gauze

WoundClot Hemostatic Gauze is a Food and Drug Administration (FDA)-cleared, next-generation hemostatic gauze made from cellulose, which is engineered to be effective in the management of mild, moderate, and severe bleeding. It is FDA approved for intraoperative use. WoundClot is also effective in the temporary management of severe bleeding during surgical procedures as well as postoperative and donorsite bleeding. It works by absorbing up to 2500% its size and weight in fluid and remains actively absorbent for up to 24 hours. This new product has multiple uses; the smaller size 2-×2-inch can be used for post-procedure wound oozing, rhinoplasty, scalp/facial lacerations, fingertip avulsions, nosebleeds, abrasions and skin tears, oozing lines, ports, and tubes. The 3-× 8-inch size can be used for gunshot and stab wounds, blunt and penetrating trauma, lacerations, and avulsions, moderate to severe venous and arterial bleeding, postpartum bleeding, and vaginal tears. For the renal dialysis patient, the gauze can be used for arteriovenous shunt site bleeding.

HemCon Nasal Plug (m.doc)

The m.doc Nasal Plugs are a polyvinyl acetal sponge with Tricol’s proprietary formulation of micro-dispersed oxidized cellulose (m.doc). The Nasal Plug expands and softens to fit the nasal cavity while it absorbs blood to control anterior nose bleeding fast. Nasal plugs offer patients an easy-to-use, quick, comfortable, and reliable solution to stop nasal bleeding without any side effects.

RevMedx’s XSTAT

XSTAT is a hemostatic device control for severe, life-threatening bleeding from junctional wounds in the groin or axillary, and bleeding from narrow entrance extremity wounds in the arms or legs not amendable by tourniquet application in adults and adolescents.

The XSTAT devise is designed to seal gun- shot wounds in the pelvis or shoulder area in about 15 seconds. It works like a syringe that injects tablet-sized sponges into the wound that then expand and provide the necessary hemostasis while the patient is transported The XSTAT device works by providing mechanical direct internal pressure inside the wound. There are no hemostatic agents of any kind. Once they come in contact with liquid, they quickly expand and create an internal compression. The sponges provide a sur- face on which blood can begin to clot. The sponges will need to be removed, and each has a tiny radiopaque marker so that any remaining in the body can be spotted on x-ray.


Hemostatic agents work in different ways to stop bleeding. Their proper use requires education on how they work with hands-on training so that they can be used correctly. All hemostatic agents were designed to be used with direct pressure at the site of the wound, even deep inside the wound, if needed.

Drew et al15 discuss the decade-long advances of battlefield medicine for the treatment of severe hemorrhage that have led to a significant reduction in mortality. The authors looked into the older methods of direct pressure, pressure points, and elevation that are no longer recommended, and recommend the use of both hemostatic agents and tourniquets for hemorrhage control that can be used by any provider in any setting. They emphasize the evidence-based advances on tourniquets for extremity injuries that occurred in battle trauma medicine since 2001. They state that these tourniquets had a pro- found effect on saving lives.

Product alert

Hemostatic agents should not be used on the eyes, airway, chest, or head injuries where there is exposed brain tissue.

Hemostatic agent uses in a hospital setting: Emergency department

If the local emergency medical services do not carry hemostatic agents, then the ED trauma team should be able to quickly and correctly apply the tourniquet and/or hemostatic agents to gain hemostasis for penetrating trauma, gunshot, or stabbing wounds.

ED trauma case

In a trauma patient with multiple gun- shot wounds who becomes hypothermic and hemodiluted, Johnson et al16 found that QCG was more effective in achieving hemostasis than standard gauze (84.6% QCG vs 30.8%, standard gauze). The QCG reduced blood loss by an average of 92.5% in a hemodiluted and hypothermic porcine model. This is easy to use; the gauze goes directly into the wound and direct pressure to the site held for at least 2 to 3 minutes until the bleeding stops.

Common occurrence: Nosebleeds

A 7-year-old boy comes to the ED with a severe nosebleed due to his hemophilia. At home, his mom did all the standard treatment of direct pressure, but the bleeding did not stop. Te Grotenhuis et al17 studied the effectiveness of HemCon Nasal Plugs in the treatment of severe epistaxis in the prehospital setting. During June 2012 to December 2014, a total of 33 patients were treated with Hem- Con Nasal Plugs. Twenty-four patients were taking anticoagulants or suffered from a clot- ting disorder. The study concluded that Hem- Con Nasal Plugs were effective adjuncts to use in severe uncontrolled epistaxis.

ED to cardiac catheterization suite, CCU hospital case

A 56-year-old man with the complaint of chest pain, shortness of breath, and nausea arrives via emergency medical services to the local ED. The ED staff meets the patient for quick assessment and up he goes to the catheterization laboratory. Due to previous catheters and scar tissue, they were un- able to gain femoral access. The radial approach is used and postcardiac catheter hemorrhage control is done by QuikClot radial pad with the Trans-Radial (TR) compression device band in place.

Postcardiac catheterization procedure CCU case

In the cardiac care/chest pain unit, the same patient is now undergoing postcardiac catheterization with a hemorrhage at the catheter insertion site. Whether this is the femoral or radial site, the standard treatment of direct pressure, occlusive dressing, pelvic binder, or TR band is unsuccessful. The critical care nurse would be able to use a proven hemostatic agent to stop the bleeding. Roberts and Niu18 reported the use of a hemostatic agent to achieve patient hemostasis of both the radial and ulnar arteries at the completion of the diagnostic and coronary interventional procedures.19 The hemostatic used was QuikClot radial hemostasis pad and the TR band. In the study, Roberts and Niu18 had 30 patients went through transradial access (TRA) coronary angiography and/or percutaneous coronary intervention were randomized into 3 cohorts post-TRA: 10 patients received mechanical compression with the TR band, 10 patients received 30 minutes of compression with the QuikClot radial pad, and 10 patients received 60 minutes of compression with the QuikClot radial pad. Times to hemostasis and access- site complications were recorded. Successful hemostasis was achieved in 100% of patients, with both the 30- and 60-minute compression groups using the QuikClot pad. Hemostasis failure occurred in 50% of patients when the TR band was initially weaned at the protocol-driven time (40 minutes after sheath removal). The study concluded that the use of the QuikClot radial pad significantly shortened hemostasis times when compared with the TR band, with no increased complications noted.

The study by Trabattoni et al20 was the first European clinical trial sought to evaluate the safety and efficacy of the QuikClot interventional hemostatic bandage used for closures after diagnostic and interventional procedures. During this study, 40 consecutive patients undergoing diagnostic angio- graphic 62% or percutaneous coronary intervention 38% by femoral approach, using a 6 (90%) or 7 (10%) French size introducer, received arterial sheath removal with the QuikClot interventional gauze used to control post-procedure bleeding. Only one hemostasis failure occurred requiring pro- longed mechanical compression. The study found that neither major bleeding, re- bleeding, nor hematoma occurred after early ambulation.


Labor and delivery case

A post-cesarean section patient had a bi- lateral tubal ligation. The patient continued to bleed after standard treatment of fundal massage, IV Pitocin, Cytotec (misoprostol), and Hemabate (carboprost tromethamine) a form of prostaglandin used to treat severe bleeding after childbirth. Despite using current standard postpartum hemorrhage medical treatments, according to Evensen et al,21 the young woman continued to bleed out for more than 4 hours. She required 2 units of packed cells, and the attending physician took her back to the operating room.

Patel et al22 demonstrated the first case of QCG used to control vaginal hemorrhage 6 years earlier in 2012. If any hemostatic agent had been used during the early stages of her postpartum hemorrhage, it most likely would have been controlled, and the surgery may not have been needed. Schmid et al23,24 used a chitosan-covered gauze that was developed for combat trauma to gain hemostasis of postpartum hemorrhage and avoided a hysterectomy.

General surgery

Liver laceration case

In the operating room controlling bleeding can be a major issue for a patient with a liver laceration. The vascular liver can bleed profusely. Baker et al25 compared hemostatic agents in an animal study for their possible use in arterial bleeding and liver lacerations. The study included 31 animals and included the monitoring of vital signs, hemodynamics, and fluid resuscitation for 4 hours. The study found the hemostatic agents were superior to the standard of care in control- ling the bleeding of organ surface and soft tissue.25


We have come a long way from using only a gauze and direct pressure in the management of hemorrhage control. These small, simple- to-use products save lives. More evidence- based outcomes are listed about the benefits of these agents.

Travers et al26 in a European journal cited the use of QCG in civil prehospital practice. Zietlow et al27 cite that both hemostatic bandages and tourniquets are effective use of translation from military experience to implementation in civilian trauma. Rowell28 asks whether civilian trauma units should change how they manage injuries that involve massive loss of blood.

QCG is now the hemostatic dressing of choice for all military personnel deploying as per the updated 2018 Committee on Tactical Combat Casualty Care.29 The selection of QuikClot is intended for common com- bat injuries. There are many new hemostatic agents, each with their own pros and cons based on the type of injury, procedure done, and location on the body. Each should be re- viewed for the specific value added for patient care.


The use of specific hemostatic agents and tourniquets should be considered in both the prehospital and in hospital settings to stop bleeding not controlled with standard treatment. It is important to keep in mind that each type of hemostatic agent should be used as designed. Formal education and skills training need to be completed as with other clinical devices used in patient care. No matter the severity of wounds or the location of the patient, whether they are in a remote village or at a metropolitan medical center, the goal is better patient survivability outcomes.


  1. Bryner J. Why we learn from our mistakes. AccessedJuly 21, 2018.
  2. Holcomb JB, Stansbury LG, Champion HR, Wade C, Bellamy RF. Understanding combat casualty care statistics. J Trauma. 2006;60(2):397-401.
  3. Eastridge BJ, Mabry RL, Seguin P, et al. Death on the battlefield (2001-2011): implications for the future of combat casualty care. J Trauma Acute Care Surg. 2012;73(6, suppl 5):S431-S437. doi:10.1097/ TA.0b013e3182755dcc.
  4. Neel S. Army aeromedical evacuation procedures in Vietnam: implications for rural America. JAMA. 1968;204(4):3090313.
  5. Bourke J. Suffering and the healing profession: the experience of military medicine in the first and second world wars. In: Arnold K, Vogel K, Peto J, eds. War and Medicine. London, England: Black Dog Publishing; 2008:108-125.
  6. Bellamy RF. The causes of death in conventional land warfare- implications for combat casualty care re- search. Mil Med. 1984;149:55-62.
  7. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. J Trauma. 1995; 38(2):185-193.
  8. Kelly JF, Ritenour AE, McLaughlin DF, et al. Injury severity and causes of death from Operation Iraqi Freedom and Operation Enduring Freedom: 2003- 2004 versus 2006. J Trauma. 2008;64(2 suppl): S21-S27.
  9. Holcomb JB, McMullin NR, Pearse L, et al. Causes of death in U.S. Special Operations Forces in the global war on terrorism, 2001-2004. Ann Surg. 2007; 245(6):986-991.
  10. Blackbourne LH, Baer DG, Eastridge BJ, et al. Military medical revolution: prehospital combat casualty care. J Trauma Acute Care Surg. 2012;73(6, suppl 5):S372- S377.
  11. Trabattoni D, Montori P, Fabbiocchi F, Lualdi A, Gatto P, Barorelli AL. A new kaolin-based haemostatic bandage compared with manual compression for bleeding control after percutaneous procedures. Eur Ra- diol. 2011,21(8):1687-1691.
  12. Lamb KM, Pithcher HT, Cavarocchi NC, Hirose H. Vascular site hemostasis in percutaneous extracorporeal membrane oxygenation therapy. Open Cardiovasc Thora Surg J. 2012:5:8-10.Accessed September 5, 2018.
  13. Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg. 2010;251(2):217-228.
  14. Kheirabadi B. Evaluation of topical hemostatic agents for combat wound treatment. US Army Med Dep J. 2011:25-37.
  15. Drew B, Bennett BL, Littlejohn L. Application of cur- rent hemorrhage control techniques for backcountry care: part one, tourniquets and hemorrhage control adjuncts. Wilderness Environ Med. 2015;26(2):236- 245. doi:10.1016/j.wem.2014.08.016.
  16. Johnson D, Bates S, Nukalo S, et al. The effects of QuikClot Combat Gauze on hemorrhage control in the presence of hemodialysis and hypothermia. Ann Med Surg (Lond). 2014;3(2):21-25.
  17. Te Grotenhuis R, van Grunsven PM, Heutz WMJM, Tan WMJM, ECTH. Use of hemostatic nasal plugs in emergency medical services in the Netherlands: a prospective study of 33 cases. Prehosp Emerg Care. 2018;22(1):91-98. doi:10.1080/10903127.2017 .1335816.
  18. Roberts JS, Niu J. A novel technique for simultaneous hemostasis of ipsilateral radial and ulnar artery access sites. Catheter Cardiovasc Interv. 2018;91(5):901- 904. doi:10.1002/ccd.27351.
  19. Roberts JS, Niu J, Pastor-Cervantes JA. Comparison of hemostasis times with a kaolin-based hemostatic pad (QuikClot Radial) vs mechanical compression (TR Band) following transradial access: a pilot prospective study. J Invasive Cardiol. 2017;29(10):328-334.
  20. Trabattoni D, Gatto P, Bartorelle AL. A new kaolin based hemostatic agent bandage use after coronary diagnostic and interventional procedures. Int J Car- diol. 2012;156(1):53-54. doi:10.1016/j.ijcard.2010. 10.030.
  21. Evensen A, Anderson J, Fontaine P. Postpartum hemorrhage: prevention and treatment. Am Fam Physician. 2017;95(7):442-449.
  22. Patel SA, Martin M, Chamales I. Vaginal hemorrhage from transobturator sling controlled with QuikClot Combat Gauze. Mil Med. 2012;177(8):997-998.
  23. Schmid BC, Rezniczek GA, Rolf N, Saade G, Gebauer G, Maul H. Uterine packing with chitosan-covered gauze for control of postpartum hemorrhage. Am J Obstet Gynecol. 2013;209(3):225.e1-e5.
  24. Schmid BC, Rezniczek GA, Rolf N, Maul H. Postpar- tum hemorrhage: use of hemostatic combat gauze. Am J Obstet Gynecol. 2012;206(1):e12-e13.
  25. Baker JE, Goodman MD, Makley AT, et al. Evaluation of a novel fibrin sealant patch in hemorrhage control after vascular or hepatic injury [pub- lished online ahead of print July 11, 2018]. Mil Med. doi:10.1093/milmed/usy168.
  26. Travers S, Lefort H, Ramdani E, et al. Hemostatic dressings in civil prehospital practice: 30 uses of QuikClot Combat Gauze. Eur J Emerg Med. 2016;23(5):391-924.
  27. Zietlow JM, Zietlow SP, Morris DS, Berns KS, Jenk- ins DH: Prehospital use of hemostatic bandages and tourniquets: translation from military experience to implementation in civilian trauma. J Spec Oper Med. 2015;15(2):48-53.
  28. Rowell W. Hemorrhage control: lessons from the military. Emerg Nurse. 2013;21(7):20-24. doi:10. 7748/en2013.
  29. The Committee on Tactical Combat Casualty Care. TCCC Guidelines for Medical Personnel.

February 27, 2023 Scientific Papers
About adminWoundclots

Leave a Reply

Your email address will not be published. Required fields are marked *

WoundClot™ | Advance Bleeding Control